Pirh2 E3 Ubiquitin Ligase Modulates Keratinocyte Differentiation Through p63

Yong-Sam Jung, Yingjuan Qian, Wensheng Yan, and Xinbin Chen§
Comparative Oncology Laboratory, University of California, Davis, CA 95616, USA

Abstract

p63, a homologue of the tumor suppressor p53, is essential for the development of epidermis and limb. p63 is highly expressed in epithelial cell layer and acts as a molecular switch that initiates epithelial stratification. However, the mechanisms controlling p63 protein level is still far from fully understood. Here, we demonstrate a regulatory protein for the p63 activity. We found that Pirh2 E3 ubiquitin ligase physically interacts with p63 and targets p63 for polyubiquitination and subsequently proteasomal degradation. We also found that ectopic expression of Pirh2 in HaCaT cells suppresses cell proliferation. Consistent with this, we found that along with altered expression of ΔNp63 protein, ectopic expression of Pirh2 promotes, whereas knockdown of Pirh2 inhibits, keratinocyte differentiation. Collectively, our data suggest that Pirh2 plays a physiologically relevant role in keratinocyte differentiation through posttranslational modification of p63 protein.

Keywords

p63; Pirh2; E3 ligase; Ubiquitination; keratinocyte differentiation

Introduction

p63, a p53 ancestor gene, is expressed as the N-terminal transactivation domain-containing (TA) and -deletion (ΔN) isoforms, the former of which is transcribed from the P1 promoter upstream of exon 1 and the latter of which from the P2 promoter in intron 3 (Yang et al., 1998). Both TA and ΔNp63 give rise to at least five C-terminal alternative spliced isoforms (α, β, γ, δ, and ε) (Mangiulli et al., 2009). Similar to p53, TAp63 is a transcription factor containing the N-terminal transactivation domain, the central DNA binding domain, and the tetramerization domain (Yang et al., 1998). Unlike p53, TA/ΔNp63α contains a C-terminal sterile alpha motif (SAM) domain involved in protein-protein interaction and regulation of development (Ponting, 1995; Yang and McKeon, 2000). It has been shown that TAp63 exerts p53-like activities in cell cycle arrest and cell death via regulating expression of some p53 target genes, including p21, Mdm2, vitamin D receptor, and Bax (Dohn et al., 2001;
Guo et al., 2009; Kommagani et al., 2006; McKeon, 2004; Senoo et al., 2007; Truong et al., 2006). While ΔNp63 lacks the N-terminal transactivation domain conserved in TAp63, it carries a unique transactivation domain, which consists of 13 unique amino acids for ΔNp63 along with the proline-rich domain (Dohn et al., 2001; Helton et al., 2006; King et al., 2003; Wu et al., 2003). It is well known that ΔNp63 plays a key role in the maintenance of proliferative potential and self-renewal of basal epidermal cells (King et al., 2003; Koster et al., 2004; Yang et al., 1998). Interestingly, the p63 gene is rarely mutated and even amplified in some cancers (Chikh et al., 2007; Flores et al., 2005; Hagiwara et al., 1999; Hibi et al., 2000) although mutation of the p53 gene is a common event in the majority of human cancers. Nevertheless, human patients and mice deficient in p63 exhibit severe abnormalities of epidermis and limb formation, indicating that p63 plays a critical role in epidermal development (Mills et al., 1999; Su et al., 2009a; Su et al., 2009b; Yang et al., 1999). Therefore, p63 is likely to be regulated in a tissue-specific manner.

The p53 protein turnover is regulated by several E3 ubiquitin ligases, including Mdm2 (Mouse double minute 2) and Pirh2 (p53-induced RING-H2) (Brooks and Gu, 2006; Leng et al., 2003; Wu et al., 1993). Interestingly, both Mdm2 and Pirh2 are RING-finger E3 ligases directly regulated by p53 and thus form a negative regulatory feedback loop with p53 to promote p53 ubiquitination and degradation (Leng et al., 2003; Wu et al., 1993). However, there are differences between Mdm2 and Pirh2. For instance, Mdm2 primarily degrades p53 in unstressed cells, but Pirh2 is able to degrade p53 upon DNA damage (Maya et al., 2001; Prives and Hall, 1999; Shieh et al., 1997). In addition, the protein stability of p73, another p53 family member, is regulated by Pirh2, but not by Mdm2 (Balint et al., 1999; Jung et al., 2011b; Ongkeko et al., 1999). Similarly, degradation of p63 protein occurs independent of Mdm2-mediated ubiquitination (Calabro et al., 2002; Galli et al., 2010). Therefore, it is likely that Mdm2 specifically polyubiquitinates and degrades p53, whereas Pirh2 is capable of regulating the protein stability of other p53 family members.

In this study, we found that p63 protein stability is regulated by Pirh2. We showed that knockdown of Pirh2 upregulates, whereas overexpression of Pirh2 downregulates, p63 expression. In addition, Pirh2 physically interacts with and polyubiquitinates p63, and consequently targets p63 for proteasome degradation. Finally, we showed that Pirh2 promotes keratinocyte differentiation via modulating ΔNp63 expression. Taken together, our findings demonstrate that Pirh2 functions as an E3 ligase for the alpha isoforms of p63 and that Pirh2 plays a physiologically relevant role in keratinocyte differentiation via posttranslational modification of p63 protein.

**Results**

**Pirh2 represses p63 expression**

In addition to Mdm2, Pirh2 has been identified as an E3 ligase regulating p53 degradation (Leng et al., 2003). Previously, we and others showed that Pirh2 polyubiquitinates and directs p73 for the proteasome-dependent degradation (Jung et al., 2011b; Wu et al., 2011). Since p63 shares a high degree of sequence identities with p53 and p73 (Joerger et al., 2009), we hypothesize that Pirh2 regulates p63 stability. To test this, Pirh2 was transiently knocked down by Pirh2 siRNA in RKO and HCT116 cells. Indeed, we found that the level...
of TAp63α protein was increased in Pirh2-knockdown (KD) cells (Figure 1a, p63 panel, compare lanes 2 and 4 with 1 and 3, respectively). We would like to note that in both RKO and HCT116 cells, TAp63α is the predominant form of p63 isoforms and can be reliably measured by Western blotting. As a positive control, p53 was also increased upon Pirh2-KD (Figure 1a, p53 panel, compare lanes 2 and 4 with 1 and 3, respectively). The level of actin was measured as a loading control. Consistent with this, we showed that the level of TAp63α protein was gradually increased as Pirh2 was progressively knocked down over a 3-day period in HCT116 cells (Figure 1b).

Next, we examined whether increased expression of Pirh2 leads to decreased expression of TAp63α protein. To test this, FLAG-tagged Pirh2 was transiently overexpressed in HCT116 and HCT116 p53−/− cells. We showed that upon ectopic expression of Pirh2, the level of TAp63α protein was decreased in HCT116 and HCT116 p53−/− cells (Figure 1c).

Next, we want to examine whether Pirh2 affects ΔNp63 expression. To test this, Pirh2 was transiently knocked down (Figure 1d) or overexpressed (Figure 1e) in HaCaT cells, which express a high level of endogenous ΔNp63α (Yang et al., 2002). Western blot analysis showed that ΔNp63α was increased by Pirh2-KD, but decreased by Pirh2 overexpression in HaCaT cells (Figure 1d and e, compare lane 2 with 1). To further examine the effect of Pirh2 on p63 degradation, Myc-TAp63α was transiently expressed in MCF7 cells along with an increased dose of FLAG-Pirh2 (Figure 1f). We showed that the levels of ectopically expressed Myc-TAp63α were decreased by FLAG-Pirh2 in a dose-dependent manner (Figure 1f, p63 panel). Similarly, the levels of endogenous ΔNp63α were decreased (Figure 1g, p63 panel) by FLAG-Pirh2 in a dose-dependent manner in HaCaT cells (Figure 1g, Pirh2 panel). Interestingly, we showed that the ability of Pirh2 to decrease the level of TAp63α and ΔNp63α was blocked by treatment with MG132 proteasome inhibitor (Figure 1f and g, compare lane 6 with 5). These data suggest that Pirh2 targets p63 for proteasomal degradation.

**Pirh2 physically associates with p63**

Since an E3 ligase often physically interacts with its substrates, we want to examine whether Pirh2 physically associates with p63. To test this, endogenous p63 and Pirh2 in RKO and HaCaT were immunoprecipitated by anti-p63 and anti-Pirh2, respectively. Western blot analysis showed that endogenous Pirh2 was detected in the TAp63α-immunocomplex (Figure 2a, top panel, lane 3). Conversely, endogenous TAp63α was detected in the Pirh2-immunocomplex (Figure 2a, bottom panel, lane 3). Likewise, endogenous Pirh2 was also detected in ΔNp63α-immunocomplex (Figure 2b, top panel, lane 3). Conversely, endogenous ΔNp63α was detected in the Pirh2-immunocomplex (Figure 2b, bottom panel, lane 3). To rule out a potential cell-type specific effect, endogenous p63 and Pirh2 were immunoprecipitated by anti-p63 and anti-Pirh2, respectively, in MIA-PaCa-2, which expresses a high level of endogenous TAp63α, and ME180, which expresses a high level of endogenous ΔNp63α. Again, we showed that Pirh2 associated with TAp63α (Figure 2c) and ΔNp63α (Figure 2d). To confirm this protein-protein association between Pirh2 and TAp63α/ΔNp63α, FLAG-tagged Pirh2 (FLAG-Pirh2) and Myc-tagged TAp63α (Myc-p63α) or ΔNp63α (Myc-ΔNp63α) were cotransfected into RKO cells, and then immunoprecipitated by anti-Myc and anti-FLAG, respectively. We showed that ectopically
expressed FLAG-Pirh2 was present in the anti-Myc (TAp63α/ΔNp63α) immunocomplexes (Figure 2e and f, top panel). Conversely, ectopically expressed Myc-p63α or Myc-ΔNp63α was detected in the anti-FLAG (Pirh2) immunocomplexes (Figure 2e and f, bottom panel). In addition, FLAG-Pirh2 was transfected into MIA-PaCa-2 and ME180 cells, and then immunoprecipitated by anti-p63 or anti-FLAG, respectively. We showed that ectopically expressed FLAG-Pirh2 was present in the anti-p63 (TAp63α/ΔNp63α) immunocomplexes (Figure 2g and h, top panel). Conversely, endogenous TAp63α or ΔNp63α was detected in the anti-FLAG (Pirh2) immunocomplexes (Figure 2g and h, bottom panel).

**Pirh2-mediated degradation of p63 occurs through a ubiquitin-dependent pathway**

To determine if the Pirh2-mediated degradation of p63 is ubiquitin-dependent, we measured the level of ectopically expressed p63 in ts20 cells at both the permissive (35°C) and nonpermissive (39°C) temperatures. The ts20 cells, a Chinese hamster lung cell line, has a thermo-inactive ubiquitin activating enzyme E1 (Chowdary et al., 1994). We found that the level of TAp63α was decreased by Pirh2 at the permissive temperature, but not much at the nonpermissive temperature (Figure 3a, compare lanes 1 and 3 with 2 and 4, respectively). As a control, we showed that endogenous p53 was destabilized at the permissive temperature but not at the nonpermissive temperature (Figure 3a, compare lane 2 and 4), consistent with previous reports that Pirh2-mediated p53 degradation is accomplished in a ubiquitin-dependent pathway (Chowdary et al., 1994; Leng et al., 2003). To confirm that reduction of TAp63α in ts20 cells is due to proteasomal degradation, ts20 cells were treated with the proteasome inhibitor MG132. We found that the level of TAp63α was not decreased upon treatment with MG132 (Figure 3a, lanes 5-8), demonstrating that the degradation of TAp63α by Pirh2 requires proteasome function. Furthermore, we examine whether Pirh2 promotes ΔNp63α degradation in ts20 cells. We showed that like TAp63α, ΔNp63α was targeted by Pirh2 for proteasomal degradation at the permissive temperature, which was blocked by treatment with MG132 (Figure 3b). Finally, we examined whether Pirh2 alters the protein half-life of TAp63α in MIA-PaCa-2 and ΔNp63α in HaCaT cells. We showed that the protein half-life of TAp63α was decreased from ~7 to 4 h (Figure 3c and d), and that of ΔNp63α was decreased from ~11 to 6 h by Pirh2 overexpression (Figure 3e and f).

**Pirh2 promotes p63 polyubiquitination**

To investigate whether Pirh2 can promote p63 degradation via ubiquitination, Myc-tagged TAp63α, and FLAG-tagged ubiquitin were co-expressed in RKO cells with FLAG-tagged Pirh2, Pirh2-ΔRING (lacks RING finger domain), or Pirh2-DN (contains two substitutive mutations from Cys to Ser at amino acids 145 and 148) (Figure 4a) (Jung et al., 2010). We showed that Myc-TAp63α was detected along with slower migrating bands by anti-Myc antibody in cells expressing Pirh2, but not Pirh2-ΔRING and Pirh2-DN (Figure 4b, top p63 panel, compare lane 4 with lanes 5-6). We also showed that the slow migrating bands were recognized by anti-ubiquitin antibody (Figure 4b, Ub panel). This suggests that the slow migrating bands are polyubiquitinated TAp63α. Similarly, ΔNp63α was polyubiquitinated by Pirh2 (Figure 4c).

Next, we investigated whether Pirh2 directly serves as an E3 ubiquitin ligase for p63. To test this, *in vitro* ubiquitination assay was performed with 35S-labeled TAp63α along with
recombinant GST-Pirh2 or GST-Pirh2-DN. We showed that TAp63α was polyubiquitinated by Pirh2 but not by Pirh2-DN (Figure 4d, compare lanes 3-4). Similarly, we also showed that ΔNp63α was polyubiquitinated by Pirh2 but not by Pirh2-DN (Figure 4e, compare lanes 3-4). Together, these data demonstrate that Pirh2 is capable of polyubiquitinating TA/ΔNp63α and promoting TA/ΔNp63α degradation.

**Pirh2 promotes keratinocyte differentiation via p63**

Striking defects in skin and limb development observed in p63 knockout mice suggest that p63 is essential for epidermal homeostasis (Mills et al., 1999; Yang et al., 1999). It has been shown that ΔNp63 is the dominant isoform expressed before epidermal stratification and throughout embryonic stages during epidermal, tooth, and hair development (Candi et al., 2007; Koster and Roop, 2004; Laurikkala et al., 2006). Indeed, abundant expression of ΔNp63 in the basal layer of stratified epithelia maintains the proliferative potential and directs proper differentiation of progenitor cells (Koster et al., 2004; Lee and Kimelman, 2002). Thus, we examined whether Pirh2 is implicated in keratinocyte differentiation. To test this, HaCaT cell line was chosen, since it has been used widely for *in vitro* keratinocyte differentiation (Deyrieux and Wilson, 2007). Since cell growth retardation is associated with differentiation, we first examined whether cell proliferation is affected by ectopic expression of Pirh2. Indeed, we found that HaCaT cell proliferation was inhibited by ectopic expression of Pirh2 (Figure 5a). Next, we examined whether Pirh2 has an impact on terminal keratinocyte differentiation, which can be measured by formation of cornified cell envelope (Pillai and Bikle, 1992). We found that knockdown of Pirh2 decreased, whereas ectopic expression of Pirh2 increased, cornified cell envelope formation induced by treatment of calcium (Figure 5b and c). In addition, we showed that knockdown of Pirh2 enhanced ΔNp63 expression but decreased expression of involucrin and filaggrin (Figure 5d). Involucrin and filaggrin are markers commonly used to measure keratinocyte terminal differentiation (Candi et al., 2005; Watt, 1983). Conversely, ectopic expression of Pirh2 decreased ΔNp63 expression but increased expression of involucrin and filaggrin (Figure 5e).

**Discussion**

All proteins are continuously turning over, as they are being hydrolyzed and replaced by *de novo* synthesis. Many proteins are degraded by the ubiquitin-dependent proteasomal pathway (Rock et al., 1994). In this study, we provide several lines of evidence to support that Pirh2 targets both TAp63α and ΔNp63α proteins for ubiquitin-dependent proteasomal degradation. First, Pirh2 physically binds to p63. Second, Pirh2 promotes p63 ubiquitination through its E3 ligase activity. Third, Pirh2 promotes p63 degradation in a ubiquitin-dependent manner. Finally, Pirh2 promotes keratinocyte differentiation via degradation of ΔNp63α.

Since its discovery as homologs of the p53 tumor suppressor, p63 and p73 have gained tremendous attention and have been intensively investigated. However, although p63 and p73 perform p53-like functions, they are not classic Knudson-Type tumor suppressors since they are key regulators in development (Melino et al., 2002). These indicate that p63 and...
p73 are not just redundant family proteins for p53. Due to the functional diversity among p53 family members, it is not surprising that p53, p63, and p73 are differentially regulated. For example, p53 stability is primarily regulated by the ubiquitin-proteasome degradation pathway via E3 ubiquitin ligases, including RING-finger E3 ligases (Mdm2, Pirh2, and COP1) and HECT-domain E3 ligases (E6-AP and Arf-BP1) (Lee and Gu, 2010). Degradation of p63 protein is mediated by Dlx3 (Di Costanzo et al., 2009), RACK1 (receptor for protein kinase C) (Li et al., 2009), and HECT-domain containing E3 ligases, including ITCH (Rossi et al., 2006) and WWP1 (Li et al., 2008). p73 ubiquitination has been shown to be regulated by ITCH (Rossi et al., 2005), FBXO45 (an F-box protein) (Peschiarioli et al., 2009), and NEDL2 (a NEDD4-related HECT-domain containing E3 ligase) (Miyazaki et al., 2003). To date, an E3 ligases that can target all the p53 family have not been reported. Here, we found that overexpression of Pirh2 decreases, whereas knockdown of Pirh2 increases, the level of TA/ΔNp63α protein (Figure 1). In addition, we showed that Pirh2 physically associates with TA/ΔNp63α (Figure 2) and promoting its polyubiquitination and degradation through proteasome (Figures 3 and 4). Together, we concluded that p63 is a substrate for Pirh2 E3 ubiquitin ligase. Previously, we and others showed that Pirh2 promotes p53/p73 protein turnover via polyubiquitinating. Thus, for the first time to our knowledge previously unreported, we showed that Pirh2 is a common E3 ubiquitin ligase for p53, p63, and p73.

The epidermis is the self-renewing stratified epithelium on the outermost layer of the skin. A variety of genes, such as involucrin, loricin, and keratins, are involved in skin formation as a barrier against the environment (Candi et al., 2005). ΔNp63α is not only the main isoform essential for epidermal development during embryogenesis, but also controls epithelial cell differentiation in the basal layer of epidermis in adult (King et al., 2003; Koster and Roop, 2004). ΔNp63α is highly expressed in basal epithelial cells and downregulation of ΔNp63α initiates differentiation (King et al., 2003; Koster et al., 2004; Yang et al., 1998). However, upstream regulator of ΔNp63α during differentiation is not clear. In this study, we found that overexpression of Pirh2 significantly inhibits cell proliferation in HaCaT cells (Figure 5a). Consistent with this, it was previously showed that depletion of ΔNp63 reduces cell viability in head and neck squamous carcinoma epithelial cells (Rocco et al., 2006). Moreover, we found that depletion of Pirh2 decreased, whereas overexpression of Pirh2 increased, the level of cornified cell envelope formation (Figure 5b and d). This suggests that Pirh2 is an important regulator in epithelial development. Since p63 is regulated by several E3 ligases, including as ITCH (Rossi et al., 2006), Mdm2/Mdmx (Calabro et al., 2002; Wang et al., 2001), WWP1 (Li et al., 2008), and SCF TrCP1 (Gallegos et al., 2008), how a proper level of p63 isoforms is maintained during skin development and/or in response to DNA damage needs to be examined. In addition, what is the upstream signal that modulates Pirh2-mediated p63 degradation during epithermal differentiation is of great interest for future studies.

As a common regulator of p53 family members, it is reasonable to speculate that Pirh2 plays a role in tumorigenesis. Indeed, evidence showed that Pirh2 may act as an oncoprotein or tumor suppressor in different types of human cancers (Jung et al., 2012). Downregulation of tumor suppressor proteins including p53, p73, and p27 may contribute to tumor progression.
in cancers with high Pirh2 expression (Duan et al., 2007; Duan et al., 2004; Duan et al., 2006). However, upregulation of oncogenic c-Myc leads to tumor formation in Pirh2 knockout mice and in cancers with low Pirh2 expression (Hakem et al., 2011). Previously, we showed that Pirh2 inhibits DNA polymerase eta (PolH) activity via degrading PolH through 20S proteasome or promoting PolH monoubiquitination (Jung et al., 2011a; Jung et al., 2010). PolH is critical in translesion DNA synthesis, and loss of PolH results in early onset of skin tumor formation upon UV-induced replication stress in PolH-knockout mice (Ohkumo et al., 2006). In addition, Pirh2 is associated with Keratin-8/18, which is abundantly expressed in epithelial cells, to regulate UV-induced cell death through modulating mitochondria distribution (Duan et al., 2009). Here, we showed that ΔNp63α is targeted by Pirh2 for proteasomal degradation. Interestingly, except its essential role in skin development and in maintaining epidermal homeostasis in adults, elevated expression of ΔNp63α is correlated with multiple epithelial cancers (Candi et al., 2007). Moreover, it has been shown that wild-type p53 mediates the suntanning response (Cui et al., 2007). Taken together, it is likely that Pirh2 plays a role in skin carcinogenesis through its targets and future studies deciphering how Pirh2 targets are involved in skin carcinogenesis will provide important clues for skin cancer treatment.

Materials and Methods

Cell Culture and Plasmids

RKO, MCF7, HaCaT, the temperature-sensitive ts20, HCT116, MIA-PaCa-2, ME180, and HCT116 p53−/− were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics. Human full-length Pirh2, Pirh2-DN (an E3 ligase defective mutant), and Pirh2-ΔRING (the RING finger domain deletion mutant) were used as previously described (Jung et al., 2010). All Pirh2 proteins were N-terminally FLAG-tagged as previously described (Jung et al., 2010). cDNAs encoding TAp63α and ΔNp63α were N-terminally Myc-tagged as previously described (Gaiddon et al., 2001). FLAG-tagged Ubiquitin expression vector in pcDNA3 was used as previously described (Jung et al., 2010).

Antibodies

Antibodies used in this study were as follow: Rabbit polyclonal anti-Pirh2 (Bethyl Laboratories), mouse monoclonal anti-p63 (Santa Cruz Biotechnology), mouse monoclonal anti-Involucrin (IVL) (Santa Cruz Biotechnology), mouse monoclonal Filaggrin (Santa Cruz Biotechnology), mouse monoclonal anti-p53 antibodies (a mixture of DO-1, PAb1801, PAb240, and PAb421) derived from hybridoma’s supernatant, mouse monoclonal anti-ubiquitin (Santa Cruz Biotechnology), rabbit polyclonal anti-Myc (Abcam), mouse monoclonal anti-FLAG (Sigma), and rabbit polyclonal anti-actin (Sigma).

Immunoprecipitation-Western Blot Analysis

The immunoprecipitation experiment was carried out as previously described (Jung et al., 2008). Briefly, cells were washed with PBS, lysed in mammalian lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.4 mM PMSF), sonicated, and cleared by centrifugation. Cell lysates (300-500 μg of total proteins) were incubated for 4
hours at 4°C with indicated antibodies coupled to the protein A/G-agarose beads (Sigma) and then washed with mammalian lysis buffer. Immunoprecipitated protein complexes and whole cell lysates (WCLs) were subjected to an SDS-PAGE. For each set, input controls were run (5% of WCL used for immunoprecipitation). IgG antibody was used as a negative control for each immunoprecipitation assay. Immuno-blots were visualized by SuperSignal West Femto Chemiluminiscent detection reagents (Pierce).

Small Interference RNA (siRNA)
Scramble and Pirh2 siRNA (sense 5′-CCAACAGACUUGUGA AGAA-dTdT-3′ and antisense 5′-UUCUUCACAAGUCUGUUGG-dTdT-3′) were purchased from Dharmacon (Junget et al., 2011a). The siRNA duplex was introduced into cells using SilentFect (Bio-Rad) according to the manufacturer’s protocol. Cells were harvested at indicated times after transfection for further experiments.

GST Fusion Protein Preparation
Glutathione S-transferase (GST)-tagged Pirh2 and Pirh2-DN were expressed by pGEX-4T-3 (Amersham Pharmacia Biotech). The recombinant GST-tagged proteins were purified as described previously (Jung et al., 2008). Briefly, the GST fusions of Pirh2 and Pirh2-DN were expressed in E. coli BL21 (DE3) (Novagen) upon induction with 0.5 mM IPTG for 4 h at 37°C. Bacterial cells were harvested and then resuspended in GST lysis buffer ((200 mM Tris-Cl, pH 8.0, 0.5 M NaCl, 100 μM EDTA, 0.1% Triton X-100, 0.4 mM phenylmethylsulfonyl fluoride). Subsequently, cell lysates were sonicated and clarified by centrifugation. GST fusion proteins were purified using glutathione-Sepharose beads (Amersham Pharmacia Biotech) according to the manufacturer’s protocol.

Ubiquitination Assay
In vivo ubiquitination assay was performed as described (Leng et al., 2003). RKO cells were transfected with indicated plasmids and treated with 5 μM MG132 for 6 h prior to harvest. Cell lysates were immunoprecipitated with anti-Myc antibody followed by Western blot with anti-Myc and anti-Ubiquitin antibodies to detect p63 ubiquitination.

In vitro ubiquitination assay using recombinant GST fusion Pirh2 proteins was performed as described (Jung et al., 2011a). 35S-labeled TAp63α and ΔNp63α proteins were mixed with GST-Pirh2 or -Pirh2-DN and then incubated on ice for 1 h to form Pirh2:p63 protein complexes. The complexes were added to ubiquitination buffer containing E1, E2, and ubiquitin, and incubated at 30°C for 2 h. Finally, the reaction mixtures were separated on SDS-PAGE and analyzed by autoradiography. E1, E2, and ubiquitin were purchased from Boston Biochem. 35S-labeled p63 was produced by the TNT T7-coupled reticulocyte lysates system (Promega).

Cell Proliferation Assay
To evaluate the calcium-induced differentiation effect on proliferation of HaCaT cells, cell proliferation assay was performed. HaCaT cells were transfected with control pcDNA3 vector or pcDNA3-2X-FLAG-Pirh2 for 24 h and then an appropriate number of cells were cultured in 6-well plates in triplicate. Cells were cultured in calcium-containing medium (1.5
mM) over a 7-day period. Cells were harvested and counted at indicated times. All values are given as mean ± SD. Statistical comparisons were made by Student’s t-test. A P value less than 0.05 was considered statistically significant.

**Cornified Cell Envelope Assay**

Cornified cell envelopes (CCEs) were analyzed as described previously (Qian et al., 2011; Zhang et al., 2010). Briefly, cells were harvested and resuspended in 1.1 ml of PBS containing 2 mM EDTA, and 100 μl aliquotes were counted for the total number of cells. The remaining cells were centrifuged and resuspended in dissociation buffer (2% SDS, 20 mM dithiothreitol, 5 mM EDTA, and 0.1 M Tris-Cl, pH 8.5), and heating for 5 min. After cooling, insoluble CCEs were harvested and resuspended in 100 μl of PBS, and counted with a hemacytometer. The data were measured as CCEs/total cells ×100. The fold-change in relative CCE is a product of CCEs induced by Pirh2 overexpression or knockdown, divided by that induced by control.

**Acknowledgments**

This work is supported in part by NIH grant CA102188.

**References**

Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene. 1999; 18:3923–9. [PubMed: 10435614]

Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006; 21:307–15. [PubMed: 16455486]

Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem. 2002; 277:2674–81. [PubMed: 11714701]

Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle. 2007; 6:274–85. [PubMed: 17264681]

Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005; 6:328–40. [PubMed: 15803139]

Chikh A, Sayan E, Thibaut S, Lena AM, DiGiorgi S, Bernard BA, et al. Expression of GATA-3 in epidermis and hair follicle: relationship to p63. Biochem Biophys Res Commun. 2007; 361:1–6. [PubMed: 17632082]

Chowdary DR, Dermody JJ, Jha KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol. 1994; 14:1997–2003. [PubMed: 8114731]

Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007; 128:853–64. [PubMed: 17350573]

Deyrieux AF, Wilson VG. In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology. 2007; 54:77–83. [PubMed: 19003021]

Di Costanzo A, Festa L, Duverger O, Vivo M, Guerrini L, La Mantia G, et al. Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle. 2009; 8:1185–95. [PubMed: 19282665]

Dohn M, Zhang S, Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene. 2001; 20:3193–205. [PubMed: 11423969]

Duan S, Yao Z, Hou D, Wu Z, Zhu WG, Wu M. Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53. EMBO J. 2007; 26:3062–74. [PubMed: 17568776]

Duan S, Yao Z, Zhu Y, Wang G, Hou D, Wen L, et al. The Pirh2-keratin 8/18 interaction modulates the cellular distribution of mitochondria and UV-induced apoptosis. Cell Death Differ. 2009; 16:826–37. [PubMed: 19282686]
Duan W, Gao L, Druhan LJ, Zhu WG, Morrison C, Otterson GA, et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst. 2004; 96:1718–21. [PubMed: 15547185]

Duan W, Gao L, Wu X, Zhang Y, Otterson GA, Villalona-Calero MA. Differential response between the p53 ubiquitin-protein ligases Pirh2 and Mdm2 following DNA damage in human cancer cells. Exp Cell Res. 2006; 312:3370–8. [PubMed: 16934800]

Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005; 7:363–73. [PubMed: 15837625]

Gaiddón C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001; 21:1874–87. [PubMed: 11238924]

Gallegos JR, Litorsky J, Lee H, Sun Y, Nakayama K, Lu H. SCF TrCP1 activates and ubiquitylates TAp63gamma. J Biol Chem. 2008; 283:66–75. [PubMed: 17965458]

Galli F, Rossi M, D’Alessandra Y, De Simone M, Lopardo T, Haupt Y, et al. Mdm2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J Cell Sci. 2010; 123:2423–33. [PubMed: 20571051]

Guo X, Keyes WM, Papazoglou C, Zuber J, Li W, Lowe SW, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol. 2009; 11:1451–7. [PubMed: 19898465]

Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 1999; 59:4165–9. [PubMed: 10485447]

Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, et al. Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet. 2011; 7:e1002360. [PubMed: 22125490]

Helton ES, Zhu J, Chen X. The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem. 2006; 281:2533–42. [PubMed: 16319057]

Hibi K, Trink B, Patturarajan M, Westra WH, Caballero OL, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000; 97:5462–7. [PubMed: 10805802]

Joerger AC, Rajagopalan S, Natan E, Veprintsev DB, Robinson CV, Fersht AR. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A. 2009; 106:17705–10. [PubMed: 19815500]

Jung YS, Hakem A, Hakem R, Chen X. Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis. Mol Cell Biol. 2011a; 31:3997–4006. [PubMed: 21791603]

Jung YS, Kim HY, Kim J, Lee MG, Pousssegur J, Kim E. Physical interactions and functional coupling between Daxx and sodium hydrogen exchanger 1 in ischemic cell death. J Biol Chem. 2008; 283:1018–25. [PubMed: 18003619]

Jung YS, Liu G, Chen X. Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation. Mol Cell Biol. 2010; 30:1041–8. [PubMed: 20008555]

Jung YS, Qian Y, Chen X. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J Biol Chem. 2011b; 286:35388–95. [PubMed: 21852228]

Jung YS, Qian Y, Chen X. Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy. FEBS Lett. 2012; 586:1397–402. [PubMed: 22673504]

King KE, Ponnampерuma RM, Yamashita T, Tokino T, Lee LA, Young MF, et al. deltaNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene. 2003; 22:3635–44. [PubMed: 12789272]

Kommagani R, Caserta TM, Kadakia MP. Identification of vitamin D receptor as a target of p63. Oncogene. 2006; 25:3745–51. [PubMed: 16462763]

Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004; 18:126–31. [PubMed: 14729569]
Koster MI, Roop DR. The role of p63 in development and differentiation of the epidermis. Journal of dermatological science. 2004; 34:3–9. [PubMed: 14757276]

Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development. 2006; 133:1553–63. [PubMed: 16524929]

Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell. 2002; 2:607–16. [PubMed: 12015968]

Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010; 17:86–92. [PubMed: 19543236]

Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003; 112:779–91. [PubMed: 12654245]

Li Y, Peart MJ, Prives C. Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation. Mol Cell Biol. 2009; 29:3953–63. [PubMed: 19451233]

Li Y, Zhou Z, Chen C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 2008; 15:1941–51. [PubMed: 18806757]

Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G, et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res. 2009; 37:6092–104. [PubMed: 19700772]

Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001; 15:1067–77. [PubMed: 11331603]

McKeon F. p63 and the epithelial stem cell: more than status quo? Genes Dev. 2004; 18:465–9. [PubMed: 15037544]

Melino G, De Laurenzi V, Vousten KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2002; 2:605–15. [PubMed: 12154353]

Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999; 398:708–13. [PubMed: 10227293]

Miyazaki K, Ozaki T, Kato C, Hanamoto T, Fujita T, Irino S, et al. A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem Biophys Res Commun. 2003; 308:106–13. [PubMed: 12890487]

Ohkumo T, Kondo Y, Yokoi M, Tsukamoto T, Yamada A, Sugimoto T, et al. UV-B radiation induces epithelial tumors in mice lacking DNA polymerase eta and mesenchymal tumors in mice deficient for DNA polymerase iota. Mol Cell Biol. 2006; 26:7696–706. [PubMed: 17015482]

Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL, et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol. 1999; 9:829–32. [PubMed: 10469568]

Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene. 2009; 28:3157–66. [PubMed: 19581926]

Pillai S, Bilek DD. Lanthanum influx into cultured human keratinocytes: effect on calcium flux and terminal differentiation. J Cell Physiol. 1992; 151:623–9. [PubMed: 1363554]

Ponting CP. SAM: a novel motif in yeast sterile and Drosophila polyhomeotic proteins. Protein Sci. 1995; 4:1928–30. [PubMed: 8528090]

Prives C, Hall PA. The p53 pathway. J Pathol. 1999; 187:112–26. [PubMed: 10341712]

Qian Y, Jung YS, Chen X. DeltaNp63, a target of DECl and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation. J Biol Chem. 2011; 286:12033–41. [PubMed: 21317427]

Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisén LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006; 9:45–56. [PubMed: 16413471]

Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994; 78:761–71. [PubMed: 8087844]
Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA, et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci U S A. 2006; 103:12753–8. [PubMed: 16908849]

Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, et al. The ubiquitin-protein ligase Itch regulates p73 stability. Embo J. 2005; 24:836–48. [PubMed: 15678106]

Senoo M, Pinto F, Crum CP, McKeon F, p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007; 129:523–36. [PubMed: 17482546]

Shieh SY, Ikeda M, Tay Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997; 91:325–34. [PubMed: 9363941]

Su X, Cho MS, Gi YJ, Ayanga BA, Sherr CJ, Flores ER. Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. Embo J. 2009a; 28:1904–15. [PubMed: 19494829]

Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL, et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell stem cell. 2009b; 5:64–75. [PubMed: 19570515]

Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev. 2006; 20:3185–97. [PubMed: 17114587]

Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K, et al. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett. 2001; 490:202–8. [PubMed: 11223036]

Watt FM. Involucrin and other markers of keratinocyte terminal differentiation. J Invest Dermatol. 1983; 81:100s–3s. [PubMed: 6345687]

Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003; 63:2351–7. [PubMed: 12750249]

Wu H, Zeinab RA, Flores ER, Leng RP. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. Mol Cancer Res. 2011; 9:1780–90. [PubMed: 21994467]

Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993; 7:1126–32. [PubMed: 8319905]

Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 2002; 18:90–5. [PubMed: 11818141]

Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998; 2:305–16. [PubMed: 9774969]

Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000; 1:199–207. [PubMed: 11252895]

Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999; 398:714–8. [PubMed: 10227294]

Zhang J, Jun Cho S, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci U S A. 2010; 107:9614–9. [PubMed: 20457941]
Figure 1. Knockdown of Pirh2 increases, whereas overexpression of Pirh2 decreases, p63 expression

(A) Cell lysates were prepared from RKO (left panel) and HCT116 (right panel) cells transfected with scramble or Pirh2 siRNA to knock down Pirh2 for 72 h. TAp63α, Pirh2, p53, and actin were measured with their respective antibodies. The level of TAp63α protein after normalization with actin was presented as fold change. (B) Cell lysates were prepared from HCT116 cells transfected with Pirh2 siRNA for 0, 24, 48, and 72 h. TAp63α, Pirh2, and actin were measured with their respective antibodies. The level of TAp63α protein after normalization with actin was presented as fold change. (C) Western blots were prepared with extracts from HCT116 (left panel) and HCT116 p53−/− (right panel) cells that were mock-transfected or transfected with FLAG-Pirh2 for 36 h. The blots were analyzed as in (A) except anti-FLAG antibody was used to detect FLAG-Pirh2. The level of TAp63α protein after normalization with actin was presented as fold change. (D) The experiment was performed as described for panel (A) except that HaCaT cells were used for transfection. The level of ΔNp63α protein after normalization with actin was presented as fold change. (E) The experiment was performed as described for panel (C) except that HaCaT cells were used for transfection. The level of ΔNp63α protein was evaluated through densitometry and results were presented as fold change. (F) Western blots were prepared with extracts from MCF7 cells transfected with Myc-TAp63α along with an increasing dose of FLAG-Pirh2 for 36 h. The blots were analyzed as in (B) except anti-FLAG antibody was used to detect FLAG-Pirh2. (G) Western blots were prepared with extracts from HaCaT cells transfected with FLAG-Pirh2 for 36 h. ΔNp63α and actin were measured with their respective antibodies. Anti-FLAG antibody was used to detect FLAG-Pirh2.
Figure 2. TAp63α and ΔNp63α isoforms bind to Pirh2

(A) Top panel: cell extracts from RKO cells were immunoprecipitated with anti-p63 (4A4) or control IgG. The immunocomplexes were then used to detect TAp63α and Pirh2 along with whole-cell lysates as input control. Bottom panel: the experiment was performed as described for top panel except that immunoprecipitation was performed with anti-Pirh2 antibody. (B) The experiments were performed as in panel (A) except HaCaT cells were used to immunoprecipitate ΔNp63α. (C) The experiments were performed as in panel (A) except MIA-PaCa-2 cells were used. (D) The experiments were performed as in panel (B) except that ME-180 cells were used. (E) The experiments were performed as in panel (A) except using anti-Myc to immunoprecipitate Myc-TAp63α (top panel) and anti-FLAG to immunoprecipitate FLAG-Pirh2 (bottom panel) in RKO cells transiently transfected with Myc-TAp63α and FLAG-Pirh2. (F) The experiments were performed as in panel (E) except RKO cells transiently transfected with Myc-ΔNp63α and FLAG-Pirh2. (G) The experiments were performed as in panel (A) except anti-FLAG was used to immunoprecipitate FLAG-Pirh2 in MIA-PaCa-2 cells transiently transfected with FLAG-Pirh2. (H) The experiments were performed as in panel (G) except MEF-180 cells were used.
Figure 3. Pirh2-mediated degradation of p63 occurs through a ubiquitin-dependent proteasomal pathway

(A) ts20 cells were transiently transfected with Myc-TAp63α along with FLAG-Pirh2 at 35°C for 24 h and then incubated at 35°C or 39°C for an additional 24 h in the presence or absence of MG132 (5 μM). The levels of FLAG-Pirh2 and Myc-TAp63α were measured by anti-FLAG and anti-Myc antibodies, respectively. Endogenous p53 and actin were measured by their respective antibodies. (B) The experiment was performed as in panel (A) except ts20 cells transiently transfected with Myc-ΔNp63α and FLAG-Pirh2. (C) The levels of TAp63α, FLAG-Pirh2, and actin were measured in extracts purified from MIA-PaCa-2 cells mock-transfected or transfected with FLAG-Pirh2 followed by treatment with CHX at the indicated times (0 to 12 h) were used to measure. (D) Calculated half-life of TAp63α, using the data from panel (C). The percentage of intensity in log$_{10}$ was plotted versus time, and the $t_{1/2}$ was calculated from the log$_{10}$ of 50%. (E) The experiment was performed as in panel (C) except that HaCaT cells were used to measure the half-life of ΔNp63α. (F) Calculated half-life of ΔNp63α, using the data from panel (C).
Figure 4. Pirh2 promotes TA/ΔNp63α polyubiquitination in vivo and in vitro

(A) Schematic presentation of Pirh2 domains (Zn Finger, Zn finger domain; RING, RING finger E3 ubiquitin ligase domain) along with location of the double point mutations and RING domain deletion. (B) Cell lysates were prepared 6 h following MG132 (5 μM) treatment from RKO cells transfected with Myc-TAp63α along with ubiquitin and wild-type or mutant Pirh2. Whole cell lysates (WCLs) were immunoprecipitated with anti-Myc antibody followed by Western blot with anti-Myc or anti-ubiquitin to detect TAp63α ubiquitination (upper panels). The levels of ectopically expressed proteins were detected with anti-Myc and anti-FLAG, respectively (lower panels). (C) The experiment was performed as in panel (B) except RKO cells transiently transfected with Myc-ΔNp63α along with ubiquitin and wild-type or mutant Pirh2. (D) In vitro ubiquitination of TAp63α was performed with GST-Pirh2 and GST-Pirh2-DN along with E1, E2, and ubiquitin. 35S-labeled reaction mixtures were separated on 8% SDS-PAGE gel and analyzed by autoradiography. (E) The experiment was performed as in panel (D) except 35S-labeled ΔNp63α was used for in vitro ubiquitination assay. The asterisk (*) represents a nonspecific band.
Figure 5. Pirh2 promotes keratinocyte differentiation

(A) HaCaT cells were transfected with a control vector or a vector expressing FLAG-Pirh2. 24 h after transfection, appropriate cells (5,000 cells) were seeded in 6-well plates in triplicate and then cultured for a 7-day period. The cell number was measured at the indicated time. Error bars represent the SD from three independent experiments (*, \( P < 0.05 \)). (B) 70-80% subconfluent HaCaT cells were cultured with defined keratinocyte-SFM medium for 24 h, then transfected with scrambled siRNA or siRNA against Pirh2 for 3 days, followed by treatment of calcium (1.5 mM) for 12 days. CCEs were analyzed as described under “Materials and Methods”. (C) HaCaT cells were transfected with a control vector or a vector expressing FLAG-Pirh2 for 24 h, followed by treatment of calcium (1.5 mM) for 12 days. (D) The level of Pirh2, \( \Delta Np63\alpha \), involucrin (IVL), filaggrin, and actin was measured in HaCaT cells used in (B). Pirh2, \( \Delta Np63\alpha \), \( \Delta Np63\beta \), IVL, filaggrin, and actin were measured with their respective antibodies. (E) The experiment was performed as in panel (D) except that HaCaT cells were transfected with a control vector or a vector expressing FLAG-Pirh2, followed by treatment of calcium (1.5 mM) for 12 days.